AtheroNova is an early stage biotech company focused on the discovery, research, development and licensing of novel compounds designed to reduce or eliminate atherosclerotic plaque deposits. AtheroNova has developed intellectual property for a class of compounds that have the potential to significantly reduce the incidence and severity of atherosclerosis.
Existing classes of cholesterol reduction drugs, including statins, have demonstrated market success, rapidly achieving blockbuster status and billions of dollars in sales without demonstrating any efficacy at reducing atherosclerosis at commonly used dosage levels. Only one study demonstrated even minimal efficacy at reducing plaque, and then only on patients taking the maximum approved dosage for two years.
Although additional research and development is required, AtheroNova has the potential to produce atherosclerosis drugs that will regress or eliminate atherosclerotic fatty plaques. The Company is currently completing two additional studies to validate the efficacy findings of its initial study and prepare for upcoming human trials. The Company plans to develop multiple applications for its compounds.
AHRO Security Details
|Market Value1 ||$30,529,182 ||a/o Nov 16, 2011 |
|Shares Outstanding ||27,753,802 ||a/o Oct 27, 2011 |
|Float ||Not Available |
|Authorized Shares ||100,000,000 ||a/o Jun 30, 2011 |
|Par Value ||0.001 |
|Shareholders of Record ||70 ||a/o Mar 31, 2011 |
- Capital Change=shs decreased by 1 for 10 split Pay date=06/30/2006.
- Capital Change=shs decreased by 1 for 200 split; + Shareholders of 1-99 shares pre-split will receive the same number of shares post-split. Shareholders of 100 - 19,999 pre-split shares will hold no fewer than 100 post-split shares. Share holders of 20,000 or more share. Pay date=06/28/2010.
AtheroNova Inc. is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. Atherosclerotic plaque, which progressively narrows and blocks arteries, is the main underlying pathology of cardiovascular disease and the leading killer in industrialized nations worldwide. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. Our Company
Key Investment Considerations
$41+ Billion market potential
Strong IP protection
Potentially lower risk of safety or efficacy problems than is typical in drug development
Strong management team with successful track record
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company is currently conducting two additional animal studies to validate the findings of its initial study and prepare for human trials. AtheroNova plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products, for the treatment of atherosclerosis. Our Technology
Our intellectual property for treating atherosclerosis began with the ideas of our two founding shareholders, Dr. Giorgio Zadini and Dr. Filiberto Zadini, co-inventors of our technology. Their research, covered by our patent applications, uses certain pharmalogical compounds for the treatment of atherosclerosis. Through a process called delipidization, such compounds dissolve plaques in artery walls so they are removed through normal body processes. The compounds go through the atherosclerotic fibrous cap and, through delipidization, cause rapid reduction in the size of the deposits of soft vulnerable plaque in an artery's walls. We also believe that the artery walls, once delipidized, will undergo a marked reduction in inflammation and ultimately undergo a significant restoration of their integrity. The compounds can be used to reverse the effects of existing atherosclerosis by widening the area in an artery through which the blood flows and avoiding the rupturing and dislodging of chunks of the hardened plaque. The compounds can also be used to prevent significant plaque buildups in arteries from occurring.
Besides applications in atherosclerosis, delipidization has significant applications in other medical fields. The delipidization of subcutaneous fat has been scientifically demonstrated by researchers at a leading U.S. academic institution, and was achieved utilizing one of the compounds determined by us to be an effective delipidizing compound. This has possibly significant implications for use in the field of clinical cosmesis, for which we have developed certain intellectual property for delipidization application to unwanted subcutaneous fat through transdermal delivery.
There are other promising potential areas of application for our intellectual property that merit further exploration and testing. We believe that systemic application of our delipidizing pharmacological compounds may have beneficial effects in the treatment of obesity and some of the disorders associated with obesity such as hypertension, diabetes, etc. We also believe that cleansing the lipid buildup from the small peripheral vessels in the body via delipidization will have beneficial effects on overall human physiology and well-being. Atherosclerosis
Atherosclerosis (from the Greek words "athero" (gruel or paste) and "sclerosis" (hardness)) is a common disease of the arteries. It occurs when organic materials, primarily cholesterol (the waxy, fat-like material found in all parts of the body) or fats, are deposited and harden in the walls of arteries. This may occur when such materials accumulate under a fibrotic cap or at a tear in the inner lining of an artery.
As the deposits harden, they can restrict and occlude the area through which the blood can flow through an artery, thereby reducing the amount of blood made available to organs and other parts of the body. Restricted blood flow in the arteries, such as to the heart muscle, can lead to symptoms such as chest pain. It also can cause tissues to receive inadequate oxygen, which is directly related to a number of circulatory disorders. For example, arteriosclerosis of the extremities is a disease of the peripheral blood vessels that is characterized by narrowing and hardening of the arteries that supply the arms, legs and feet. The narrowing of the arteries causes a decrease or cessation in blood flow. Symptoms include pain, numbness, cold tissues and hypoxia resulting in cellular death.
Hardened plaques can also rupture and dislodge from an artery's walls, and then greatly restrict or block altogether blood flow through that or other arteries. This can lead to heart attacks and other severe disorders. For example, strokes can be caused when ruptured plaques in a neck artery impede the flow of blood to parts of the brain and decrease brain functions.
Cardiovascular disease is the leading cause of morbidity, disability and mortality in industrialized countries, and atherosclerosis is its main underlying pathology. Timeline
We are currently conducting two progressive laboratory studies of the technology. These studies are expected to cost approximately $400,000 and take 6-8 months to complete, and an additional 3-4 months to determine the final results. Market
The global medical industry presently, through many large and small health care providers and other vendors of goods and services, generates substantial cash flows directly related to the treatment of symptomatic atherosclerotic disease. The clinical applications of our intellectual property are expected to be a novel class of pharmacological compounds for treating and preventing atherosclerosis, suitable for parenteral, oral, transdermal and in-loco methods of delivery. The therapeutic applications of our intellectual property within such a variety of clinical modalities are likely to be both synergistic and disruptive to the types of clinical care presently applied within the atherosclerosis-related markets.
Existing markets sectors, with their approximate annual cash flows, include Serum Screening ($3 Billion), Imaging ($12 Billion), Diagnostic Catheterizations ($12 Billion), Statin Drug Therapies ($10 Billion) and Drug Eluting Stents ($6 Billion). In addition, incalculable investment dollars are applied to emerging therapeutic technologies for cardiovascular diseases. Safety and Regulatory Approvals
The compounds used in our technology have a history of approval for use in humans by regulatory government agencies in a large number of developed countries throughout the world, including Germany, England, France, and Italy, and have been used in humans throughout the world, including in the USA, for their medical indications. The existing human safety record for this class of compounds, at higher concentrations than we required in our initial research, is well established for uses other than those which we have claimed in our intellectual property. Use of the compounds in such other medical configurations, though approved, is limited to non-competing clinical applications that cannot be diverted or used off-label for the uses covered by our patent applications. Barchart.com Technical Analysis